A bankruptcy judge Friday approved the sale of the assets of Dendreon Corp., a troubled cancer drug maker, to Valeant Pharmaceuticals International Inc. for $495 million.
via WSJ.com: US Business http://ift.tt/1FEJVWZ
via WSJ.com: US Business http://ift.tt/1FEJVWZ
Nessun commento:
Posta un commento